Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Multicenter, Open-Label Phase 1/2a Study of Pxs-5505 and Ruxolitinib in Patients with Primary, Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) Myelofibrosis

Peter Tan, Ross Baker, Sung-Eun Lee, Anne Marie Watson, Stanley Cheung, Shang-Ju Wu, Chih-Cheng Chen, Shuhying Tan, Pankit Vachhani, Tsai-Yun Chen, Jae Hoon Lee, Hui-Hua Hsiao, Ji Yun Lee, Won Sik Lee, Lucia Masarova, Jana Baskar, Wolfgang Jarolimek, Joanna Leadbetter

Blood (2024) 144 (Supplement 1): 1001.

https://doi.org/10.1182/blood-2024-204290

Published: 2024

Journal Articles

Second Transplant Offers the Possibility of Long Term Graft-Versus-Host-Disease-Free Relapse-Free Survival

Betty Gration, Sandra Ware, Georgina Calov, Mark Barrios, Anne Marie Watson, David Gottlieb, Matthew Greenwood, Stephen Robert Larsen, Jacinta Perram

Blood (2024) 144 (Supplement 1): 4952.

https://doi.org/10.1182/blood-2024-203096

Published: 2024

Journal Articles

Real-World Patterns of Care and Outcomes for Non-Favourable Risk Acute Myeloid Leukemia Treated with Intensive Chemotherapy across Australia and New Zealand- Data Linkage between the ALLG National Blood Cancer Registry (NBCR) and the Australia and New Zealand Transplant and Cellular Therapy (ANZTCT) Registry

Blood (2024) 144 (Supplement 1): 3799.

https://doi.org/10.1182/blood-2024-209389

Published: 2024

Journal Articles

The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma

Blood (2024) 143 (2): 152–165.

https://doi.org/10.1182/blood.2023021348

Published: 2024

Includes: Supplemental data

Journal Articles

PXS5505-MF-101: A Phase 1/2a Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Pxs-5505 in Patients with Primary, Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

Pankit Vachhani, Jana Baskar, Brett Charlton, Stanley Cheung, Wolfgang Jarolimek, Sung-Eun Lee, Peter Tan, Anne Marie Watson, Shang-Ju Wu

Blood (2023) 142 (Supplement 1): 625.

https://doi.org/10.1182/blood-2023-181383

Published: 2023

Journal Articles

Phase 1/2a Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of Pxs-5505 in Patients with Primary, Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

Ross Baker, Jana Baskar, Brett Charlton, Gabriela S. Hobbs, Wolfgang Jarolimek, Sung-Eun Lee, Lucia Masarova, Anne-Marie Watson

Blood (2022) 140 (Supplement 1): 3947–3948.

https://doi.org/10.1182/blood-2022-158344

Published: 2022

Journal Articles

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3 mut+ AML ineligible for intensive chemotherapy

Blood (2022) 140 (17): 1845–1857.

https://doi.org/10.1182/blood.2021014586

Published: 2022

Includes: Supplemental data

Journal Articles

Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome

Amer M. Zeidan, Uma Borate, Daniel A. Pollyea, Andrew M. Brunner, Fernando Roncolato, Jacqueline S. Garcia, Robin J Filshie, Olatoyosi Odenike, Anne-Marie Watson, Ravi Krishnadasan, Ashish Bajel, Kiran Naqvi, Jiuhong Zha, Leah Hogdal, Ying Zhou, David Hoffman, Steve Kye, Guillermo Garcia-Manero

Blood (2021) 138 (Supplement 1): 537.

https://doi.org/10.1182/blood-2021-145646

Published: 2021

Journal Articles

Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3 -Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy

Blood (2021) 138 (Supplement 1): 700.

https://doi.org/10.1182/blood-2021-145379

Published: 2021

Journal Articles

Peripheral Blood Haploidentical Allogeneic Stem Cell Transplantation in Older Adults with AML/MDS Demonstrates Excellent Long Term Overall Survival, Results from the Australasian Bone Marrow Transplant Recipient Registry

Edward Abadir, Jad Othman, John Kwan, David J Gottlieb, Glen A Kennedy, Ashish Bajel, Richard Doocey, Travis Perera, Anne-Marie Watson, Peter G Bardy, Matthew Greenwood, David J. Curtis, Steven Tran, John Moore, Nada Hamad

Blood (2021) 138 (Supplement 1): 2929.

https://doi.org/10.1182/blood-2021-149939

Published: 2021

Journal Articles

Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma Can Achieve Durable Remission and Myeloablative Conditioning Is Associated with Inferior Survival: An Australasian Bone Marrow Transplant Recipient Registry Study

Pietro R Di Ciaccio, BA/LLB MBBS FRACP FRCPA, David Ritchie, MB ChB, PhD FRACP, FRCPA, Glen A Kennedy, MBBS FRACP FRCPA, Sam Milliken, MBBS, FRACP, FRCPA, Duncan Purtill, MBBS,FRCPA,FRACP, David Gottlieb, MBBS, MD FRACP, FRCPA, Travis Perera, MB ChB, FRACP, FRCPA, David T Yeung, BSc,PhDFRACP,FRCPA,MBBS, Stephen R Larsen, MBBS PhDFRACP FRCPA, Richard Doocey, MB ChB, FRACP, FRCPA, Matthew Greenwood, MBBS, FRACP, FRCPA, Simon Durrant, MBBS FRCP FRCPath, Anne-Marie Watson, FRACP, FRCPA, MBBS, Andrew Butler, MB ChB(Edin), MRCP, MRCPath, Amit Khot, MBBS, MD MRCP, FRCPath, FRACP, Cameron Curley, MBBS, FRACP, FRCPA, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-139057

Published: 2020

Journal Articles

Allogeneic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma Can Achieve Durable Remissions: An Australasian Bone Marrow Transplant Recipient Registry Study

Pietro R Di Ciaccio, BA/LLB MBBS FRACP FRCPA, Matthew Greenwood, MBBS, FRACP, FRCPA, Glen A Kennedy, MBBS FRACP FRCPA, Sam Milliken, MBBS, FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, David Ritchie, MB ChB, PhD FRACP, FRCPA, Duncan Purtill, MBBS,FRCPA,FRACP, Stephen R Larsen, MBBS PhDFRACP FRCPA, Andrew Spencer, Travis Perera, MB ChB, FRACP, FRCPA, David T Yeung, BSc,PhDFRACP,FRCPA,MBBS, Simon Durrant, MBBS FRCP FRCPath, Andrew Butler, MB ChB(Edin), MRCP, MRCPath, Anne-Marie Watson, FRACP, FRCPA, MBBS, Hock Choong Lai, MBBS, FRACP, FRCPA, Richard Doocey, MB ChB, FRACP, FRCPA, Hugh J. Goodman, FRACP, Ian H. Kerridge, FRACP FRCPA MPhil BA, Christopher Arthur, Cameron Curley, MBBS, FRACP, FRCPA, Caroline Stewart, Kenneth P. Micklethwaite, MBBS, PhD FRACP, FRCPA, Jennifer Collins, Julian Cooney, FRACP,FRCPA,MBBS,, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-139076

Published: 2020

Journal Articles

An Australasian Bone Marrow Transplant Registry (ABMTR) Study of the Trends and Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) in Hodgkin Lymphoma between 2009-2019: Relapse Remains the Most Common Cause of Death Post Transplantation

Kirsty M Sharplin, MBBS, David Ritchie, MB ChB, PhD FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, Ian Bilmon, BMBS, FRACP, FRCPA, Shyam Panicker, MBBS,MDMRCP,FRACP,FRCPA, Glen A Kennedy, MBBS FRACP FRCPA, Cameron Curley, MBBS, FRACP, FRCPA, Duncan Purtill, MBBS,FRCPA,FRACP, Julian Cooney, FRACP,FRCPA,MBBS,, Richard Doocey, MB ChB, FRACP, FRCPA, Leanne Berkahn, MD, Sam Milliken, MBBS, FRACP, FRCPA, Pietro R Di Ciaccio, BA/LLB MBBS FRACP FRCPA, Peter G Bardy, MBBS, FRACP, FRCPA, FRCPath, Andrew Spencer, David J. Curtis, MBBS,PhD, Sushrut S. Patil, Stephen R Larsen, MBBS PhDFRACP FRCPA, Travis Perera, MB ChB, FRACP, FRCPA, Andrew Butler, MB ChB(Edin), MRCP, MRCPath, Matthew Greenwood, MBBS, FRACP, FRCPA, Anne-Marie Watson, FRACP, FRCPA, MBBS, Hock Choong Lai, MBBS, FRACP, FRCPA, Eric Wong, MDPhD FRACP, FRCPA, Steven Tran, BEng MBiomedE, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-138684

Published: 2020

Journal Articles

Survival Outcomes for Plasmablastic Lymphoma: An International, Multicentre Study By the Australasian Lymphoma Alliance

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-134972

Published: 2020

Journal Articles

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome

Blood (2019) 134 (Supplement_1): 565.

https://doi.org/10.1182/blood-2019-124994

Published: 2019

Journal Articles

Early Treatment Intensification with R-ICE Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) Using Zevalin-BEAM for Patients with Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) As Identified By Interim PET/CT Scan Performed after Four Cycles of R-CHOP-14: A Multicenter Phase II Study of the Australasian Leukaemia Lymphoma Study Group (ALLG)

Blood (2015) 126 (23): 815.

https://doi.org/10.1182/blood.V126.23.815.815

Published: 2015

Journal Articles

Phase II Pilot Study of Imatinib Mesylate Combined with Induction Chemotherapy in Blast-Phase CML and Ph+ ALL.

Jason Lickliter, MD, Chris Arthur, MD, James D’Rozario, MD, Chi-hung Hui, MD, Jeffrey Szer, MD, Kerry Taylor, MD, Anne-Marie Watson, MD, Jennifer McCarron, BSc, Kevin Lynch, MD, Ken Bradstock, MD, PhD

Blood (2004) 104 (11): 4682.

https://doi.org/10.1182/blood.V104.11.4682.4682

Published: 2004

NARROW

Multicenter, Open-Label Phase 1/2a Study of Pxs-5505 and Ruxolitinib in Patients with Primary, Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) Myelofibrosis

Second Transplant Offers the Possibility of Long Term Graft-Versus-Host-Disease-Free Relapse-Free Survival

The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma

PXS5505-MF-101: A Phase 1/2a Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Pxs-5505 in Patients with Primary, Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

Phase 1/2a Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of Pxs-5505 in Patients with Primary, Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3 mut+ AML ineligible for intensive chemotherapy

Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome

Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3 -Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy

Peripheral Blood Haploidentical Allogeneic Stem Cell Transplantation in Older Adults with AML/MDS Demonstrates Excellent Long Term Overall Survival, Results from the Australasian Bone Marrow Transplant Recipient Registry

Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma Can Achieve Durable Remission and Myeloablative Conditioning Is Associated with Inferior Survival: An Australasian Bone Marrow Transplant Recipient Registry Study

Allogeneic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma Can Achieve Durable Remissions: An Australasian Bone Marrow Transplant Recipient Registry Study

An Australasian Bone Marrow Transplant Registry (ABMTR) Study of the Trends and Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) in Hodgkin Lymphoma between 2009-2019: Relapse Remains the Most Common Cause of Death Post Transplantation

Survival Outcomes for Plasmablastic Lymphoma: An International, Multicentre Study By the Australasian Lymphoma Alliance

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome

Phase II Pilot Study of Imatinib Mesylate Combined with Induction Chemotherapy in Blast-Phase CML and Ph+ ALL.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only